Mass. Eye and Ear makes History with Gene Therapy

NEC Member Massachusetts Eye and Ear recently announced its first injection of a gene therapy drug, Luxterna, which treats a form of blindness, following approval of the therapy by the FDA in December 2017.

Gene therapies modify a patient’s DNA by inserting healthy genes into cells to replace faulty or missing ones. The newly-approved treatment involves injecting a modified virus into a patient’s eyes to correct a deficiency caused by mutations in the RPE65 gene which prevent the production or function of a protein needed for proper functioning of the retina. Jason Comander, M.D., Ph.D., associate director of the hospital’s inherited retina disorders service, performed the procedure on a thirteen -year-old boy from New Jersey using the gene therapy drug which is manufactured by Spark Therapeutics.

“I am so excited the time has come when we can offer this groundbreaking therapy to our patients, who are truly in need of our help,” Dr. Comander said.

While costly, gene therapies have the potential to cure a wide range of diseases and have spawned scores of new biotechs in recent years, including several in Massachusetts. Massachusetts Eye and Ear is one of eight medical centers in the country that is certified to inject Luxterna in patients and remains the only site to do so in New England

The New England Council applauds Massachusetts Eye and Ear for being the first in the region to offer gene therapy treatments and looks forward to its continued success. Read more in Massachusetts Eye and Ear’s press release and in the Boston Business Journal.


Recently from the Blog

New England College finds success in recruiting diverse student body

07/23/2021 | Read Post

Fidelity Digital to expand staff by 70% due to strong crypto demand

07/23/2021 | Read Post

In the News

NEC Board Elects Three New Directors

04/27/2021 | Read Press Release

NEC Endorses Cannabis Banking Legislation

04/1/2021 | Read Press Release